21 search results for: biologics

Indirect Treatment Comparison of <b>Biologics</b> Approved for CRSwNP
Rhinology
Indirect Treatment Comparison of Biologics Approved for CRSwNP
expert video

In this video soundbite from the ERS-ISIAN 2025 symposium, Dr. Sietze Reitsma discusses about indirect comparison of biologics for CRSwNP, focusing on clinical outcomes like symptom relief and safety and also highlights dupilumab, omalizumab, and mepolizumab as effective and well-tolerated options.

View more
CRSwNP at Center Stage: Impact of <b>Biologics</b> in Patients with Co-existing Type 2 Asthma
Pulmonology
CRSwNP at Center Stage: Impact of Biologics in Patients with Co-existing Type 2 Asthma
expert video

In this video soundbite from the EAACI 2025 symposium, Dr. Philippe Gevaert explains how biologic options for uncontrolled CRSwNP are increasing, and phase 3 studies of approved biologics show improved outcomes and decreased SCS use/surgery in patients with CRSwNP. Additionally, he explains how biologics targeting type 2 inflammatory pathophysiology potentially improve outcomes for eligible patients with co-existing CRSwNP and asthma.

View more
CEORL-HNS 2026 | Emerging Evidence of <b>Biologics</b> for the Treatment Landscape of CRSwNP
Rhinology
CEORL-HNS 2026 | Emerging Evidence of Biologics for the Treatment Landscape of CRSwNP
expert video

Join Sanofi and Regeneron for an educational symposium on type 2 inflammation, patient characteristics predictive of disease recurrence, and emerging real-world evidence for biologics in CRSwNP.

View more
Head-to-Head Trials of <b>Biologics</b> in CRSwNP
Rhinology
Head-to-Head Trials of Biologics in CRSwNP
expert video

In this video soundbite from the ERS-ISIAN 2025 symposium, Dr. Sietze Reitsma discusses findings from the EVEREST trial, the first head-to-head study comparison of dupilumab and omalizumab in patients with severe CRSwNP and coexisting asthma. It also introduces the ongoing TORNADO study.

View more
Event Page Thumbnail
Congress
27
April
2026
Congress
ADVENT at CEORL-HNS 2026

Join Sanofi and Regeneron for an educational symposium on type 2 inflammation, patient characteristics predictive of disease recurrence, and emerging real-world evidence for biologics in CRSwNP.

From Data to Decision: Unleashing Real-World Evidence for Smart Treatment Selection 
Dermatology
From Data to Decision: Unleashing Real-World Evidence for Smart Treatment Selection 
expert video

Dr. Pedro Bastos shares how real-world evidence for approved biologics is essential to inform the treatment of PN across diverse comorbid patient populations, including insights into rapid itch relief, progressive skin clearance, long-term outcomes, and safety.

View more
Transforming Prurigo Nodularis Care in 2026: New Real-World Evidence for Comprehensive Care and Treatment Optimization
Dermatology
Transforming Prurigo Nodularis Care in 2026: New Real-World Evidence for Comprehensive Care and Treatment Optimization
expert video

Join Drs. Sarina Elmariah and Pedro Bastos to explore the full systemic burden of prurigo nodularis, looking beyond the nodules to discover how real-world evidence for approved biologics can inform treatment decisions and long-term care across diverse patient populations.

View more
ADVENT at EADV 2026
On Demand
Transforming Prurigo Nodularis Care in 2026: New Real-World Evidence for Comprehensive Care and Treatment Optimization

Drs. Sarina Elmariah and Pedro Bastos led an engaging ADVENT Industry Hub at EADV 2026 in Vienna, Austria, exploring the full systemic burden of prurigo nodularis (PN) beyond its visible nodules. The session highlighted how real-world evidence for approved biologics can inform treatment decisions and support long-term disease management across diverse patient populations.

2025 ADVENT Forum | Latest Clinical Data from the COPD Biologic Treatment Landscape
Pulmonology
2025 ADVENT Forum | Latest Clinical Data from the COPD Biologic Treatment Landscape
expert video

Explore the dynamic advancements in COPD biologic therapies. Prof. Klaus Rabe, MD, Prof. Claus Vogelmeier, MD, and Prof. Wisia Wedzicha, MD, present and analyze the latest clinical data, offering key insights into current and emerging therapeutic strategies for managing COPD.

View more
Differential Effects of Dupilumab and JAK Inhibitors on CCL17 (TARC) in Patients With AD
Dermatology
Differential Effects of Dupilumab and JAK Inhibitors on CCL17 (TARC) in Patients With AD
expert video

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares compares the effects of biologics and JAK inhibitors on the biomarker CCL17 (TARC) in atopic dermatitis.

View more
ADVENT at IRS-ISIAN | The Importance of Understanding Smell Loss and Congestion in CRSwNP
Congress
5
April
2024
Congress
ADVENT at IRS-ISIAN | The Importance of Understanding Smell Loss and Congestion in CRSwNP

Join Profs. Sachio Takeno and Joaquim Mullol for an educational symposium highlighting the multifaceted burden associated with loss of smell and congestion in patients with uncontrolled CRSwNP.

Expert Insights on the Management of Bullous Pemphigoid: The Canadian Treatment Guidelines
Dermatology
Expert Insights on the Management of Bullous Pemphigoid: The Canadian Treatment Guidelines
expert video

Fiona Lovegrove, MD, PhD, reviews Canadian consensus recommendations for the diagnosis and management of bullous pemphigoid (BP).

View more